Kenneth C. Anderson is an American hematologist-oncologist and cancer researcher who is primarily known for advances in the treatment of multiple myeloma. He directs the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana–Farber Cancer Institute and is the Kraft Family Professor of Medicine and Vice Chair of the Joint Program in Transfusion Medicine at Harvard Medical School.
Kenneth C. Anderson | |
|---|---|
| Alma mater | |
| Scientific career | |
| Fields | Oncology |
| Institutions | |
Biography
editAnderson completed medical school and residency training at the Johns Hopkins School of Medicine, and he completed an oncology fellowship at Dana–Farber Cancer Institute. He continued his medical career at Dana-Farber as a physician and researcher with a special interest in multiple myeloma.[1] Anderson sits on the board of directors for the Multiple Myeloma Research Foundation and chairs the organization's scientific advisory committee.[2]
In 2010, Anderson was elected to the Institute of Medicine.[3] The American Association for Cancer Research elected him a fellow of the AACR Academy in 2015.[4] In 2017, he served as the president[5] of the American Society of Hematology (ASH). He is a past recipient of ASH's William Dameshek Prize.[1] Anderson is the editor-in-chief of the journal Clinical Cancer Research.[6]
References
edit- ^ a b "2016 ASH President-Elect: Kenneth C. Anderson, MD". www.hematology.org. January 27, 2016. Retrieved December 13, 2016.
- ^ "Kenneth Anderson, MD - Multiple Myeloma Research Foundation". Multiple Myeloma Research Foundation. 9 September 2014. Retrieved December 13, 2016.
- ^ "Institute of Medicine elects 65 new members, five foreign associates". Retrieved December 13, 2016.
- ^ "Kenneth C. Anderson, MD". American Association for Cancer Research. Retrieved December 13, 2016.
- ^ "2017 ASH President: Kenneth C. Anderson, MD". hematology.org. Retrieved March 9, 2019.
- ^ "Editorial Board". clincancerres.aacrjournals.org. Retrieved December 13, 2016.